Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients was conducted. Results: 448 patients were enrolled (65% female, median age 68 years): 45% belonged to Group M, 40% to Group MP and 15% to Group P. Significant differences (M vs. MP vs. P) were detected in terms of rate of chronic infection due to any bacteria (30% vs. 47% vs. 71%, p<0.001), P. aeruginosa (20% vs. 32% vs. 58%, p<0.001) and other bacteria (14% vs 19% vs 25%, p=0.038). Median predicted FEV1 was statistically different among the groups (M:88% vs. MP:77% vs. P:72%, p<0.001) as well as the median Bronchiectasis Severity Index values (M:6 vs. MP:8 vs. P:9, p<0.001). Quality of life was significantly poorer in Group P vs. MP vs. M (QoL-B respiration score: 52 vs. 61 vs. 70, p<0.001). Differences in hospitalization rate (M: 10% vs P: 33%) and 3+ exacerbation/year (M 41% vs P 58%) were detected in follow up. The exclusion of COPD did not affect the results. Conclusion: Murray sputum chart is a valuable tool to assess disease severity and might be useful to predict clinical outcomes in Bx. Footnotes Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2673.

Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE) / E. Franceschi, S. Aliberti, F. Dente, M. Berlendis, E. De Juli, M.S. Battaglia, A. Gramegna, F. Amati, M. Contarini, C. Calabrese, V. Conio, V. Comellini, N. Crimi, A. Corsico, P. Faverio, S. Ferri, C. Galeone, F. Menzella, S. Nava, P. Paggiaro, N. Scichilone, M. Dottorini, R. Di Matteo, M. Dodaj, J. D Chalmers, G. Sotgiu, F.B.A. Blasi. ((Intervento presentato al convegno ERS tenutosi a Paris nel 2018.

Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)

E. Franceschi;S. Aliberti;M.S. Battaglia;A. Gramegna;F. Amati;M. Contarini;F.B.A. Blasi
2018

Abstract

Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients was conducted. Results: 448 patients were enrolled (65% female, median age 68 years): 45% belonged to Group M, 40% to Group MP and 15% to Group P. Significant differences (M vs. MP vs. P) were detected in terms of rate of chronic infection due to any bacteria (30% vs. 47% vs. 71%, p<0.001), P. aeruginosa (20% vs. 32% vs. 58%, p<0.001) and other bacteria (14% vs 19% vs 25%, p=0.038). Median predicted FEV1 was statistically different among the groups (M:88% vs. MP:77% vs. P:72%, p<0.001) as well as the median Bronchiectasis Severity Index values (M:6 vs. MP:8 vs. P:9, p<0.001). Quality of life was significantly poorer in Group P vs. MP vs. M (QoL-B respiration score: 52 vs. 61 vs. 70, p<0.001). Differences in hospitalization rate (M: 10% vs P: 33%) and 3+ exacerbation/year (M 41% vs P 58%) were detected in follow up. The exclusion of COPD did not affect the results. Conclusion: Murray sputum chart is a valuable tool to assess disease severity and might be useful to predict clinical outcomes in Bx. Footnotes Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2673.
Settore MED/10 - Malattie dell'Apparato Respiratorio
Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE) / E. Franceschi, S. Aliberti, F. Dente, M. Berlendis, E. De Juli, M.S. Battaglia, A. Gramegna, F. Amati, M. Contarini, C. Calabrese, V. Conio, V. Comellini, N. Crimi, A. Corsico, P. Faverio, S. Ferri, C. Galeone, F. Menzella, S. Nava, P. Paggiaro, N. Scichilone, M. Dottorini, R. Di Matteo, M. Dodaj, J. D Chalmers, G. Sotgiu, F.B.A. Blasi. ((Intervento presentato al convegno ERS tenutosi a Paris nel 2018.
Conference Object
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/667617
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact